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The Structural Basis of Estrogen
Receptor/Coactivator Recognition and the
Antagonism of This Interaction by Tamoxifen
endogenous estrogen 17b-estradiol (E2) and the syn-
thetic nonsteroidal estrogen diethylstilbestrol (DES),
function as pure agonists, whereas others, such as ICI-
164,384, function as pure antagonists. Synthetic ligands
such as tamoxifen and raloxifene (RAL) belong to a
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growing class of molecules known as selective estrogenUniversity of California at San Francisco
receptor modulators (SERMs), which function as antag-San Francisco, California 94143-0448
onists in specific tissue and promoter contexts (Grese²The Ben May Institute for Cancer Research
et al., 1997). The remarkable tissue-specific behavior ofand Department of Biochemistry and Molecular Biology
tamoxifen was recently demonstrated in the NationalUniversity of Chicago
Surgical Adjuvant Breast and Bowel Project±sponsoredChicago, Illinois 60637
Breast Cancer Prevention Trial (Smigel, 1998). In the³Metabolic Research Unit
group of women at high risk for breast cancer who re-University of California
ceived tamoxifen treatment, there was an increased inci-San Francisco, California 94143
dence of endometrial cancer but a reduced occurrence
of certain bone fractures and a dramatic 45% reduction
in breast cancer incidence. The rational design of new
Summary SERMs and the optimization of existing ones require an
understanding of the effects of different ligand chemis-
Ligand-dependent activation of transcription by nu- tries and structures upon ERa transcriptional activity.
clear receptors (NRs) is mediated by interactions with Transcriptional activation by ERa is mediated by at
coactivators. Receptor agonists promote coactivator least two separate activation functions (AFs), AF-1 in
binding, and antagonists block coactivator binding. the N terminus, and AF-2 in the LBD. The activity of
Here we report the crystal structure of the human AF-1 is regulated by growth factors acting through the
MAP kinase pathway (Kato et al., 1995), while AF-2 activ-estrogen receptor a (hERa) ligand-binding domain (LBD)
ity is responsive to ligand binding (Kumar et al., 1987).bound to both the agonist diethylstilbestrol (DES) and
The binding of agonists triggers AF-2 activity, whereasa peptide derived from the NR box II region of the
the binding of antagonists does not (Berry et al., 1990).coactivator GRIP1 and the crystal structure of the hERa
Recent structural studies suggest that ligands regu-LBD bound to the selective antagonist 4-hydroxytamox-
late AF-2 activity by directly affecting the structure ofifen (OHT). In the DES-LBD-peptide complex, the pep-
the LBD. Comparison of the structure of the unligandedtide binds as a short a helix to a hydrophobic groove
human retinoid X receptor a LBD (Bourguet et al., 1995)on the surface of the LBD. In the OHT-LBD complex,
with the structures of the agonist-bound LBDs of thehelix 12 occludes the coactivator recognition groove
human retinoic acid receptor g (RARg) (Renaud et al.,by mimicking the interactions of the NR box peptide
1995) and other NRs suggests that an agonist-inducedwith the LBD. These structures reveal the two distinct
conformational change involving the repositioning of he-mechanisms by which structural features of OHT pro-
lix 12, the most C-terminal helix of the LBD, is essentialmote this ªautoinhibitoryº helix 12 conformation.
for AF-2 activity (Moras and Gronemeyer, 1998). Be-
cause certain point mutations in helices 3, 5, and 12
abolish AF-2 activity but have no effect on ligand or DNA
Introduction binding, these regions of the LBD have been predicted to
form part of a recognition surface, created in the pres-
Estrogens exert their physiological effects by binding ence of agonist, for molecules that link the receptor to
to the estrogen receptors, which are members of the the general transcriptional machinery (Danielian et al.,
nuclear receptor (NR) superfamily of ligand-inducible 1992; Wrenn and Katzenellenbogen, 1993; Henttu et al.,
transcription factors (Tsai and O'Malley, 1994; Beato et 1997; Feng et al., 1998).
al., 1995). The estrogen receptor a (ERa) regulates the The structures of the LBD complexed with E2 and RAL
differentiation and maintenance of neural, skeletal, car- show that, although both ligands bind at the same site
diovascular, and reproductive tissues (Korach, 1994; within the core of the LBD (Brzozowski et al., 1997),
Smith et al., 1994). Compounds that modulate ERa tran- each of these ligands induces a different conformation
of helix 12. Whereas helix 12 in the E2-LBD complexscriptional activity are currently being used to treat os-
packs against helices 3, 5/6, and 11 in a conformationteoporosis, cardiovascular disease, and breast cancer
that has been observed for the corresponding helix in(Gradishar and Jordan, 1997; Jordan, 1998).
other agonist-bound NR LBD structures, helix 12 in theAll ERa ligands bind exclusively to the C-terminal li-
RAL-LBD complex is bound in a hydrophobic groovegand-binding domain (LBD). The LBD recognizes a vari-
composed of residues from helices 3 and 5. This alterna-ety of compounds diverse in their size, shape, and chem-
tive orientation of helix 12 partially buries residues inical properties. Some of these ligands, including the
the groove that are necessary for AF-2 activity, sug-
gesting that RAL and possibly other antagonists block
AF-2 function by disrupting the topography of the AF-2§ To whom correspondence should be addressed (e-mail: agard@
msg.ucsf.edu or ggreene@huggins.bsd.uchicago.edu). surface.
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Several proteins, including SRC-1/N-CoA1 (Onate et
al., 1995; Kamei et al., 1996), GRIP1/TIF2/N-CoA2 (Hong
et al., 1996; Voegel et al., 1996; Torchia et al., 1997;),
p/CIP/RAC3/ACTR/AIB1 (Anzick et al., 1997; Chen et
al., 1997; Li et al., 1997; Torchia et al., 1997), and CBP/
p300 (Hanstein et al., 1996), associate in a ligand-depen-
dent manner with the ERa. These proteins have been
classified as transcriptional coactivators because they
enhance ligand-dependent transcriptional activation by
the ERa as well as by several other NRs (Horwitz et al.,
1996; Glass et al., 1997). SRC-1 and GRIP1 bind to the
agonist-bound LBDs of both the human thyroid receptor
Figure 1. Views of the Electron Density of the DES-ERa LBD-GRIP1b (TRb) and human ERa using the putative AF-2 interac-
NR Box II Peptide Complex and of the OHT-ERa LBD Complextion surface (Feng et al., 1998). Members of the p160
(A) A view of a 2Fo2Fc electron density map of the DES-LBD-peptidefamily of coactivators, such as SRC-1 and GRIP1, as
complex calculated at 2.03 AÊ resolution and contoured at 1.0 swell as other coactivators, recognize agonist-bound NR
showing the GRIP1 NR box II interaction with the LBD. The peptideLBDs through a short signature sequence motif, LXXLL
was omitted from the model prior to map calculation. Ile-689 from
(where L is leucine and X is any amino acid), known as the peptide and two of the three receptor residues with which it
the NR box (Le Douarin et al., 1996; Heery et al., 1997; interacts (Glu-542 and Leu-539) are labeled. Asp-538 has been omit-
Torchia et al., 1997; Ding et al., 1998). Mutagenesis stud- ted for clarity. The hydrogen bonds between the g-carboxylate of
Glu-542 and the amides of residues 689 and 690 of the peptide areies indicate that the affinity of coactivators for NR LBDs
depicted as dashed orange bonds.is determined principally, if not exclusively, by these NR
(B) A view of a 2Fo2Fc electron density map of the OHT-LBD complexboxes (Le Douarin et al., 1996; Heery et al., 1997; Torchia
calculated at 1.90 AÊ resolution and contoured at 1.0 s showing the
et al., 1997; Ding et al., 1998). N-terminal region of helix 12. The dashed orange bonds depict the
The structural mechanisms by which binding of differ- water-mediated hydrogen bond network between the imidazole ring
ent ligands to ERa influences coactivator recruitment of His-377, the g-carboxylate of Glu-380, and the amide of Tyr-537.
The three labeled residues (Glu-380, Leu-536, and Tyr-537) interactremain unclear. We have chosen to examine the struc-
with each other through van der Waals contacts and/or hydrogentural and functional effects on the LBD of the binding
bonds.of two chemically related compounds, the agonist, DES,
and the selective antagonist, 4-hydroxytamoxifen (OHT),
the active metabolite of tamoxifen (Grainger and Met-
1998). In the present study, an electrophoretic mobilitycalfe, 1996). Here we report the 2 AÊ resolution structure
shift assay was used to demonstrate that the NR box IIof the ERa LBD bound to both DES and a peptide with
peptide bound the ERa LBD in the presence of the ago-the sequence of the second NR box (NR box II) from
nist DES but not the antagonist OHT (data not shown).the p160 coactivator GRIP1, and the 1.9 AÊ X-ray crystal
In combination, these observations suggest that the NRstructure of the human ERa LBD bound to OHT. In the
box II peptide is a valid model for studying the interactionDES complex, the NR box peptide is bound in an
between GRIP1 and the ERa LBD.a-helical conformation by a hydrophobic groove formed
In order to characterize structurally the interactionby residues from helices 3, 4, 5, and 12 and the turn
between the GRIP1 NR box II peptide and the ERa LBD,between helices 3 and 4. In the OHT complex, rather
recombinant human ERa LBD (residues 297±554) wasthan forming part of a functional AF-2 surface, helix 12
crystallized bound to both DES and the peptide. Thebinds to and occludes the coactivator recognition site
ERa LBD bound to OHT was also crystallized in orderby mimicking the interactions formed by an NR box with
to determine the mechanism by which this antagonistthe LBD. The two distinct mechanisms by which specific
blocks coactivator/ERa interaction. X-ray diffractionstructural features of OHT direct this alternative confor-
data from these crystals were measured, and the struc-mation of helix 12 are discussed.
tures were determined by a combination of molecular
replacement (using a modified version of the coordi-Results
nates of the RARg LBD [Renaud et al., 1995] as the
search model) and aggressive density modification (seeStructure Determination
Experimental Procedures). The structure of the DES-GRIP1, a mouse p160 coactivator, interacts both in vivo
ERa LBD-NR-box II peptide complex has been refinedand in vitro with the ERa LBD bound to agonist (Ding
to a crystallographic R factor of 19.9% (Rfree 5 25.0%)et al., 1998), but not with the LBD bound to antagonist
using data to 2.03 AÊ resolution (Figure 1A and Table 1).(Norris et al., 1998). Mutational studies of GRIP1 and its
The structure of the OHT-ERa LBD complex has beenhuman homolog TIF2 suggest that of the three NR boxes
refined using data to 1.90 AÊ to a crystallographic R factorfrom GRIP1, NR box II (residues 690 to 694) binds most
of 23.0% (Rfree 5 26.2%) (Figure 1B and Table 1).tightly to the ERa LBD (Ding et al., 1998; Voegel et al.,
1998). Competition assays indicate that a 13-residue
Overall Structure of the DES-LBD-NRpeptide, NH2-KHKILHRLLQDSS-CO2H (residues 686 to
Box II Peptide Complex698 from GRIP1), containing NR box II, binds specifically
The asymmetric unit of the DES-LBD-NR box II peptideto the agonist-bound ERa LBD (IC50 , 0.4 mM; P. J. K.,
complex crystals contains the same noncrystallographicunpublished) and to other agonist-bound NR LBDs (Dar-
imont et al., 1998 [see Note Added in Proof]; Ding et al., dimer of LBDs that has been observed in the previously
Molecular Mechanisms of Agonism and Antagonism of ERa
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Table 1. Summary of Crystallographic Statistics
Data Collection
Ligand DES OHT
Space group P21 P6522
Resolution 2.03 1.90
Observations 104,189 269,253
Unique 30,265 23,064
Completeness (%) 98.4 99.1
Rsym (%)a 7.8 7.0
Average I/sI 9.8 16.1
Refinement
No. of nonhydrogen atoms 4,180 2,069
Rcryst (%)b/Rfree (%) 19.9/25.0 23.0/26.2
Bond rms deviation (AÊ ) 0.005 0.006
Angle rms deviation (8) 1.05 1.04
Average B factor (AÊ 2) 34.0 40.4
a Rsym 5 Si|Ii 2 ,Ii.|/SiIi, where ,Ii. is the average intensity over
symmetry equivalents.
b Rcryst 5 S|Fo 2 Fc|/S|Fo|.
determined structures of the LBD bound to both E2 and
RAL (Brzozowski et al., 1997; Tanenbaum et al., 1998). Figure 2. Overall Structures of the DES-ERa LBD-GRIP1 NR Box II
Peptide Complex and of the OHT-ERa LBD ComplexThe conformation of each LBD complexed with DES
(A) Two orthogonal views of the DES-ERa LBD-NR box II peptideclosely resembles that of the LBD bound to E2 (Brzozow-
complex. The coactivator peptide and the LBD are shown as ribbonski et al., 1997); each monomer is a wedge-shaped mole-
drawings. The peptide is colored gold, and helix 12 (residues 538±cule consisting of three layers of 11 to 12 helices and
546) is colored magenta. Helices 3, 4, and 5 (labeled H3, H4, and
a single beta hairpin (Figure 2A). One NR box II peptide H5, respectively) are colored blue. DES, colored green, is shown in
is bound to each LBD in a hydrophobic cleft composed space-filling representation.
of residues from helices 3, 4, 5, and 12 and the turn (B) Two orthogonal views of the OHT-ERa LBD complex similar to
those of the agonist complex in (A). The LBD is depicted as a ribbonbetween 3 and 4 (Figures 2A and 3A). The density for
drawing. As in (A), helix 12 (residues 536±544) is colored in magenta,both peptides in the asymmetric unit is continuous and
and helices 3, 4, and 5 are colored blue. OHT, in red, is shown inunambiguous (Figure 1A). Residues 687 to 697 from
space-filling representation.
peptide A and residues 686 to 696 from peptide B have
been modeled; the remaining residues are disordered.
side chains of Ile-358, Lys-362, Leu-372, Gln-375, Val-Given that each peptide lies within a different environ-
376, and Leu-379 (Figures 3A and 3C). In contrast, thement within the crystal, it is striking that from residues
side chains of both Ile-689 and the second NR boxIle-689 to Gln-695 each peptide forms a two-turn, amphi-
leucine, Leu-693, rest against the rim of the groove (Fig-pathic a helix (Figures 2A and 3A). Flanking this region
ures 3A and 3C). The side chain of Ile-689 lies in aof common secondary structure, the peptides adopt
shallow depression formed by the side chains of Asp-dissimilar random coil conformations.
538, Leu-539, and Glu-542. The side chain of Leu-693
makes nonpolar contacts with the side chains of Ile-358The NR Box II Peptide-LBD Interface
and Leu-539.
The binding of the NR box II peptide to the ERa LBD
In addition to interacting with the hydrophobic face
buries 1000 AÊ 2 of predominantly hydrophobic surface of the peptide helix, the LBD stabilizes the main chain
area from both molecules. The NR box II peptide-binding conformation of the NR box peptide by forming capping
site is a shallow groove composed of residues Leu-354, interactions with both ends of the peptide helix. Glu-
Val-355, Ile-358, Ala-361, and Lys-362 from helix 3; Phe- 542 and Lys-362 are positioned at opposite ends of the
367 and Val-368 from helix 4; Leu-372 from the turn peptide-binding site (Figure 3A). The g-carboxylate of
between helices 3 and 4; Gln-375, Val-376, Leu-379, and Glu-542 hydrogen bonds to the amides of the residues
Glu-380 from helix 5; and Asp-538, Leu-539, Glu-542, of N-terminal turn of the peptide helix (residues 688 and
and Met-543 from helix 12 (Figure 3A). The floor and 689 of peptide A; residues 689 and 690 of peptide B)
sides of this groove are completely nonpolar, but the (Figure 1A). Similarly, the e-amino group of Lys-362 hy-
ends of this groove are charged (Figure 3C). drogen bonds to the carbonyls of the residues of the
The LBD interacts primarily with the hydrophobic face C-terminal turn of the peptide helix (residue 693 of pep-
of the NR box II peptide a helix formed by the side tide A; residues 693 and 694 of peptide B) (Figure 5).
chains of Ile-689 and the three LXXLL motif leucines The side chain of Gln-375 also forms a water-mediated
(Leu-690, Leu-693, and Leu-694). The side chain of Leu- hydrogen bond to the carbonyl of residue 694.
690 is deeply embedded within the groove and forms To test the importance of the NR box peptide/LBD
van der Waals contacts with the side chains of Ile-358, interface observed in the crystal, a series of site-directed
Val-376, Leu-379, Glu-380, and Met-543 (Figures 3A and mutations were introduced into the LBD. These muta-
3C). The side chain of Leu-694 is similarly isolated within tions were designed either to perturb the nonpolar char-
acter of the floor of the binding groove (Ile-358→Arg,the groove and makes van der Waals contacts with the
Cell
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Val-376→Arg, and Leu-539→Arg) or to prevent the for-
mation of the capping interactions (Lys-362→Ala and
Glu-542→Lys) (Feng et al., 1998). Fusions of glutathione
S-transferase (GST) to the wild-type and mutant LBDs
were analyzed for their ability to bind 35S-labeled GRIP1
in the absence of ligand or in the presence of DES or
OHT. Only the wild-type GST-LBD was able to recognize
the coactivator in the presence of DES (Figure 3E), con-
firming the importance of the observed capping and
hydrophobic packing interactions.
Agonist Recognition
In its receptor complex, DES, like E2 (Brzozowski et al.,
1997), is completely encased within the narrower half
of the LBD in a predominantly hydrophobic cavity com-
posed of residues from helices 3, 6, 7, 8, 11, and 12 as
well as the S1/S2 hairpin (Figures 2A and 4A).
The interaction of DES with ERa resembles that of E2.
One of the phenolic rings of DES lies in the same position
as the E2 A ring near helices 3 and 6. Like the aromatic
ring of the E2, the DES A ring (Figure 4A) is engaged by
the side chains of Phe-404, Ala-350, Leu-387, and Leu-
391 with its phenolic hydroxyl forming hydrogen bonds
to the g-carboxylate of Glu-353, to the guanidinium
group of Arg-394, and to a structurally conserved water
molecule. The A9 ring of DES (Figure 4A) is bound near
helices 7, 8, and 11 adjacent to the location of the E2 CFigure 3. The NR Box II Peptide/DES-LBD Interface and the Helix
and D rings. This ring forms van der Waals contacts not12/OHT-LBD Interface
only with Gly-521 and Leu-525, like the D ring of E2, but(A) A close-up view of the coactivator peptide bound to the DES-
also with Met-343, Leu-346, and Met-421 (Figure 4A).LBD complex. The regions of the LBD that do not interact with the
Even though it is located 1.7 AÊ from the position of thepeptide have been omitted for clarity. Helices 3, 4, and 5 are labeled
H3, H4, and H5, respectively. The side chains of the receptor resi- D ring hydroxyl, the DES A9 ring phenolic hydroxyl is
dues that interact with the peptide are depicted. Except for Lys- still able to hydrogen bond to the imidazole ring of His-
362 (blue) and Glu-542 (red), the side chains are colored by atom 524 (Figure 4A).
type (carbon and sulfur atoms are colored green, oxygen atoms are
DES also forms contacts with the LBD that E2 doescolored red, and nitrogen atoms are colored blue). Helix 12 is colored
not. There are unoccupied cavities adjacent to the amagenta. The peptide, colored gold, is depicted as a Ca worm; only
face of the B ring and the b face of the C ring of the E2the side chains of Ile-689 and the three motif leucines (Leu-690,
Leu-693, and Leu-694) are drawn. (Brzozowski et al., 1997; Tanenbaum et al., 1998). The
(B) A close-up view of the OHT-LBD complex showing helix 12 ethyl groups of DES, which project perpendicularly from
bound to part of the coactivator-binding site. Only the side chains the plane of the phenolic rings, fit snugly into these
of residues that interact with helix 12 are drawn (with the exception
spaces. The resulting additional nonpolar contacts withof the side chain of His-373, which is omitted for clarity). Except for
the side chains of Ala-350, Leu-384, Phe-404, and Leu-Lys-362 (blue) and Glu-380 (red), the side chains are colored by
428 (Figure 4A) may account for the higher affinity ofatom type (as specified in [A]). Residues 530±551 are depicted as
a Ca worm; residues 536±544 are colored magenta. The side chains DES for the receptor (Kuiper et al., 1997).
of Leu-536, Tyr-537, Leu-540, Met-543, and Leu-544 are shown. Except for Met-421 and Met-528 (both of which con-
(C) A molecular surface representation of the LBD bound to DES tact only DES) and Met-388 and Ile-424 (both of which
colored according to the local electrostatic potential (blue 5 posi-
contact only E2), the ER is able to use the same residuestive; red 5 negative) as calculated in GRASP (Nicholls et al., 1991).
to form all of the observed hydrogen bonds and van derThe coactivator peptide is depicted as in (A) and the view is equiva-
Waals contacts with both of these distinctly shapedlent to that in (A). The side chains of Leu-690 and Leu-694 are bound
in a hydrophobic groove, and those of Ile-689 and Leu-693 rest agonists (Figure 4A and Brzozowski et al., 1997; Tanen-
against the edge of this groove. baum et al., 1998). This remarkable adaptability is pre-
(D) A molecular surface representation of the LBD bound to OHT sumably the result of both the relatively large molecular
colored as in (C). Residues 530±551 are depicted as in (B) and the volume of the binding pocket (z500 AÊ 3 in both com-
view is equivalent to that in (B). Whereas the side chains of Leu-
plexes) and its apparent structural plasticity. In particu-540 and Leu-544 are embedded in the hydrophobic groove, that of
lar, at the DES A9 ring/steroid D ring end of the bindingMet-543 lies along the edge of this groove.
pocket, Met-343, Met-421, His-524, and Met-528 adopt(E) 35S-labeled GRIP1 was incubated with either immobilized gluta-
thione S-transferase (GST), immobilized wild-type GST-hERa LBD different packing configurations in response to each
(WT), or immobilized mutant GST-LBDs in the absence of ligand (2) ligand (data not shown).
or in the presence of DES (D) or OHT (T). Thirty picomoles of each of
the GST-LBDs were immobilized, as described in the Experimental
Structure of the OHT-LBD ComplexProcedures. The bound GRIP1 was visualized by fluorography after
The binding of OHT induces a conformation of the LBDSDS-PAGE. The input lane represents the total amount of 35S-GRIP1
that differs in both secondary and tertiary structural or-included in each binding reaction. All of the mutations in the LBD
disrupt agonist-dependent binding of GRIP1. ganization from that driven by DES binding. In the DES
Molecular Mechanisms of Agonism and Antagonism of ERa
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Figure 4. DES Interactions with the LBD (A)
and OHT Interactions with the LBD (B)
Residues that interact with the ligands are
drawn at approximately their true positions.
The residues that form van der Waals con-
tacts with ligand are depicted as labeled arcs
with radial spokes that point towards the li-
gand atoms with which they interact. The res-
idues that hydrogen bond to ligand are shown
in ball-and-stick representation. Hydrogen
bonds are represented as dashed cyan lines;
the distance of each bond is given. The ligand
rings and the individual ligand atoms are la-
beled.
complex, the main chain from residues 339 to 341, 421 N- and C-terminal capping interactions. Lys-362 inter-
acts with the C-terminal turn of helix 12 much as it doesto 423, and 527 to 530 forms parts of helices 3, 8, and
11, respectively. In contrast, these regions adopt an with the equivalent turn of the peptide helix (Figures
3A and 3B). The Lys-362 side chain packs against theextended conformation in the OHT complex (Figures 2A,
2B, and 6A). In addition, the composition and orientation C-terminal turn of helix 12 with its e-amino group hydro-
gen bonding to the carbonyls of residues 543 and 544of helix 12 are different in the two structures. Helix 12
in the DES complex consists of residues 538 to 546, (Figure 5). Given that the capping interaction at the
N-terminal turn of the coactivator helix is formed by awhereas helix 12 in the OHT complex consists of resi-
dues 536 to 544. Most dramatically, rather than covering helix 12 residue (Glu-542), the N-terminal turn of helix
12 in the antagonist complex is stabilized by anotherthe ligand-binding pocket as it does in the DES complex,
helix 12 in the OHT complex occupies the part of the residue, Glu-380 (Figures 3B and 3D). The Glu-380
g-carboxylate forms van der Waals contacts with Tyr-coactivator-binding groove formed by residues from
helices 3, 4, and 5 and the turn connecting helices 3 537 and interacts with the amide of Tyr-537 through a
series of water-mediated hydrogen bonds (Figure 1B).and 4 (Figures 2A, 2B, and 3B). This alternative confor-
mation of helix 12 appears to be similar to that observed In addition to forming these ªNR box±likeº interac-
tions, helix 12 also forms van der Waals contacts within the RAL complex (Brzozowski et al., 1997).
areas of the LBD outside of the coactivator recognition
groove. The side chain of Leu-536 forms van der WaalsHelix 12±LBD Interface
Except for the orientation of helix 12, the structure of contacts with Glu-380 and Trp-383, and that of Tyr-537
forms van der Waals contacts with His-373, Val-376,the peptide-binding groove is almost identical in the
DES-LBD-NR box II peptide, OHT-LBD, and E2-LBD
complexes (Figures 3A and 3B) (Brzozowski et al., 1997).
We therefore refer to the region of this groove outside
of helix 12 as the ªstatic regionº of the NR box±binding
site (Feng et al., 1998). Helix 12 in the OHT complex and
the NR box peptide helix in the DES complex interact
with the static region of the coactivator recognition
groove in strikingly similar ways.
Helix 12 mimics the hydrophobic interactions of the
NR box peptide with the static region of the groove
with a stretch of residues (residues 540 to 544) that
resembles an NR box (LLEML instead of LXXLL). The
side chains of Leu-540 and Met-543 lie in approximately
Figure 5. Comparison of Helix 12 from the OHT Complex and thethe same locations as those of the first and second motif
NR Box II Peptideleucines (Leu-690 and Leu-693) in the peptide complex
The structures of the OHT-LBD complex and the DES-LBD-NR box(Figure 5). Leu-540 is inserted into the groove and makes
II peptide complex were overlapped using the Ca coordinates ofvan der Waals contacts with Leu-354, Val-376, and Glu-
residues 306±526 of the LBD. Helix 12 from the DES-LBD-coactiva-380 (Figures 3B and 3D). Met-543 lies along the edge
tor peptide complex is omitted for clarity. Residues 536±551 (helix
of the groove and forms van der Waals contacts with 12 5 residues 536±544) from the OHT-LBD complex are colored
the side chains of Leu-354, Val-355, and Ile-358 (Figures magenta, and the peptide is colored gold. For the OHT-LBD com-
plex, the hydrogen bonds between the e-amino group of Lys-3623B and 3D). The side chain position of Leu-544 almost
and the backbone carbonyls of residues 543 and 544 of helix 12exactly overlaps that of the third NR box leucine, Leu-
are illustrated as dashed magenta bonds. For the DES-LBD-peptide694 (Figure 5). Deep within the groove, the Leu-544 side
complex, the hydrogen bonds between the e-amino group of Lys-chain makes van der Waals contacts with the side chains
362 and the backbone carbonyls of residues 693 and 696 of the
of Ile-358, Lys-362, Leu-372, Gln-375, Val-376, and Leu- coactivator peptide are depicted as dashed orange bonds. Helix
379 (Figures 3B and 3D). 12: L540 5 Leu-540; M543 5 Met-543; L544 5 Leu-544. Peptide:
L690 5 Leu-690; L693 5 Leu-693; L694 5 Leu-694.Helix 12 in the OHT complex is also stabilized by
Cell
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and Glu-380 (Figures 1B, 3B, and 3D). As a result of
these contacts, helix 12 in the OHT complex buries more
solvent-accessible surface area (z1200 AÊ 2) than the NR
box peptide in the DES complex.
OHT Recognition
OHT is bound within the same pocket that recognizes
DES, E2, and RAL. The orientation of OHT within the
binding pocket appears to be dictated by the positioning
of two structural features of this ligand, the phenolic A
ring and the bulky side chain (Figures 4B and 6C). The
A ring of OHT is bound in approximately the same loca-
tion as the A ring of DES near helices 3 and 6, with its
phenolic hydroxyl hydrogen bonding to a structurally
conserved water and to the side chains of Glu-353 and
Arg-394 (Figure 4B). Like the bulky side chain of RAL,
the side chain of OHT exits the binding pocket between
helices 3 and 11 (Figures 2B and 4B). The OHT C ring
(Figure 4B) forms van der Waals contacts with the side
chains of Met-343, Leu-346, Thr-347, Ala-350, Trp-383,
Leu-384, Leu-387, and Leu-525. The positioning of the
flexible dimethylaminoethyl region of the side chain is
stabilized by van der Waals contacts with Thr-347, Ala-
350, and Trp-383 and by a salt bridge between the di-
methylamino group of the side chain and the b-carboxyl-
ate of Asp-351, which lies 3.8 AÊ away (Figure 4B). The
positions of the A ring and the side chain in the context
of the rigid triphenylethylene framework of OHT requires
that the ethylene group of OHT lie in an orientation nearly
orthogonal to that of the ethylene group of DES (Figures
4A, 4B, and 6D). As a result, the B ring of OHT is driven
Figure 6. The Binding of Agonists and Antagonists Promote Differ-more deeply into the binding pocket than the A9 ring of
ent LBD ConformationsDES (Figures 6B and 6C).
(A) Ribbon representations of the DES complex (without the coacti-This location of the OHT B ring apparently cannot be
vator peptide), the OHT complex, and the E2 complex of Tanenbaumaccommodated by the same mechanisms that allow the et al. (1998). The hormones are shown in space-filling representation.
DES A9 ring/E2 D ring end of the binding pocket to adapt In each complex, helix 12 is colored magenta, and the main chain
to the different structural features of DES and E2. In- of residues 339 to 341, 421 to 423, and 527 to 530 is colored red.
Helices 3, 8, and 11 (H3, H8, and H11, respectively) are labeled instead, the residues that contact the B ring (Met-343,
the DES complex.Leu-346, Met-421, Ile-424, Gly-521, His-524, and Leu-
(B) A cross section of a space-filling model of the LBD bound to525), most of which also interact with the A9 ring of DES,
DES (green) showing the ligand completely embedded in the ligand-
adopt conformations distinct from the ones they adopt binding cavity. The A9 ring of DES (A9), Phe-404 (404), Met-421 (421),
in the DES structure (Figure 6D). In fact, the location of and Phe-425 (425) are labeled. The carbon atoms of side chain of
the B ring actually precludes the side chain of one resi- Met-421 are colored magenta, and the sulfur atom is colored yellow.
(C) A cross section of a space-filling model of the LBD bound todue, Met-421, from adopting the same conformation
OHT (red). The view is equivalent to that in (B). The B rings of OHTthat it adopts in the DES structure (Figures 6B and 6C).
(B), Phe-404 (404), Met-421 (421), and Phe-425 (425) are labeled.As a consequence of these B ring±induced side chain
The side chain of Met-421 is colored as in (B). The conformation of
conformations, many interresidue van der Waals con- the B ring forces Met-421 to adopt a different conformation than
tacts present in the DES complex are absent in the OHT the one it adopts in the DES complex (compare with [B]).
complex. For example, whereas Met-421 packs against (D) The structures of the OHT complex and the DES complex were
overlapped as in Figure 5. OHT is colored red, and DES is coloredHis-524 from helix 11 and against Met-343 from helix 3
green. The A rings of both ligands point out of the page; the B ringin the agonist complexes, it is precluded by the location
of OHT and the A9 ring of DES point into the page. The LBD boundof the OHT B ring from interacting with either of these
to OHT is colored blue, and the LBD bound to DES is colored light
residues in the antagonist complex (Figure 6D). gray. The side chains of some of the residues whose conformations
The structural effects of the placement of the B ring are dramatically different between the two complexes are drawn:
are not limited to the residues that contact the B ring; Met-342 (342); Met-343 (343); Phe-404 (404); Met-421 (421); Ile-424
(424); Phe-425 (425); His-524 (524); Leu-525 (525); Met-528 (528).the conformations of these residues force other residues
The sulfur atom of Met-421 is colored yellow in both structures.throughout the binding pocket to, in turn, adopt alterna-
tive conformations. For instance, the conformation of
Met-421 in the OHT complex prevents the side chains residues that directly contact the B ring and those that
are indirectly affected by it force the main chain through-of Phe-404 and Phe-425 from occupying the positions
they take in the DES complex (Figures 6B and 6C). The out the binding pocket to adopt a different conformation
as well (Figure 6D).alternative conformations of the side chains of both the
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Discussion of the OHT- and RAL-liganded ERa LBDs is that helix
12 is bound to the static region of the coactivator recog-
nition groove (Figure 3B and Brzozowski et al., 1997). AThe AF-2 Surface and NR Box Recognition
The structure of the ERa LBD in complex with the GRIP1 comparison of these two structures with the structure
of the coactivator/LBD complex reveals that in the an-NR box II peptide reveals that the LXXLL motif forms
the core of a short amphipathic a helix that is recognized tagonist complexes, the region of helix 12 with an NR
box±like sequence (LXXML versus LXXLL) functions asby a highly complementary groove on the surface of the
receptor. In agreement with the conclusions of other an intramolecular mimic of the coactivator helix (Figure
5 and Brzozowski et al., 1997). Consistent with the pro-mutational and structural studies (Brzozowski et al.,
1997; Feng et al., 1998), we propose that this peptide- posals of others (Brzozowski et al., 1997; Darimont et
al., 1998), this disposition of helix 12 directly affects thebinding groove formed by residues from helices 3, 4, 5,
and 12 and the turn between helices 3 and 4 is the AF-2 structure and function of the AF-2 surface in two ways.
First, because helix 12 residues form an integral part ofsurface of ERa.
Of the eleven AF-2 residues whose side chains inter- the AF-2 surface, the AF-2 surface is incomplete when
helix 12 is in the antagonist-bound conformation. In par-act with the coactivator helix (Figure 3A), only four (Lys-
362, Leu-379, Gln-375, and Glu-542) are highly con- ticular, Leu-539, Glu-542, and Met-543 are incorrectly
oriented for coactivator recognition. Second, residuesserved across the nuclear receptor family (Wurtz et al.,
1996). The side chains of Gln-375 and Leu-379 are pre- from the static region of the AF-2 surface are bound to
helix 12 and are prevented from interacting with coacti-dominantly buried even in the absence of GRIP1 binding
and appear to form integral parts of the architecture of vator (Figures 3A and 3B).
The sequence similarity of helix 12 of the ERa LBD tothe AF-2 surface. In contrast, the side chains of Lys-
362 and Glu-542 are largely solvent exposed in the ab- the LXXLL motif is not shared by all other NRs; the
identities of the residues in this region of helix 12 insence of coactivator and make both nonpolar contacts
and the only direct receptor-mediated polar interactions most NRs, although generally hydrophobic in character,
do not as closely resemble the sequence of an NR boxwith the coactivator helix. These two capping interaction
residues are perfectly positioned at opposite ends of as those of ERa (Wurtz et al., 1996). However, it is possi-
ble that an intramolecular inhibitor with a suboptimalthe AF-2 surface groove not only to stabilize the main
chain conformation of the coactivator but also to func- recognition sequence would compete for coactivator
binding given its extremely high local concentration.tion as a molecular caliper; the 15 AÊ distance between
Lys-362 and Glu-542 is well suited to measure off the Therefore, it will be necessary to determine if the antago-
nists of other NRs act by the same mechanism.z11 AÊ axial length of the short, two-turn coactivator
a helix (Figure 3C). Similar receptor-mediated capping
interactions have also been observed in a complex be-
The Structural Basis of OHT Antagonismtween the TRb LBD and the NR box II peptide (Darimont
The binding of OHT to ERa promotes a helix 12 confor-et al., 1998). Mutation of either of these two capping
mation that inhibits binding of coactivator. OHT doesinteraction residues severely cripples coactivator bind-
not directly interact with any helix 12 residues (Figureing by ERa as well as by TRb (see Results and Henttu
4B). Moreover, the structure of the LBD in the region ofet al., 1997; Feng et al., 1998). Hence, the formation of
the AF-2 surface groove that interacts with helix 12 in thehelix-capping interactions may be a general feature of
OHT complex is the same in the DES and E2 complexescoactivator recognition by NRs.
(Figures 3A, 3B, and 5) (Brzozowski et al., 1997). So howThe hydrophobic face of the NR box helix is formed
does OHT binding influence the position of helix 12?by the side chains of the three motif leucines and the
Numerous studies have demonstrated the importanceisoleucine preceding the motif (Ile-689). The functional
of the OHT side chain in receptor antagonism (Jordanimportance of the conserved leucines in receptor bind-
and Gosden, 1982; Robertson et al., 1982). A compari-ing has been demonstrated by numerous studies (Le
son of the structures of the OHT and DES complexesDouarin et al., 1996; Heery et al., 1997; Torchia et al.,
reveals that the binding mode of the OHT side chain1997; Ding et al., 1998; Voegel et al., 1998). Structural
precludes the agonist-induced conformation of helix 12.and biochemical data in this study implicate Ile-689 as
The OHT side chain projects out of the ligand-bindinganother key ERa-binding determinant. In the crystal,
pocket between helices 3 and 11 (Figures 2B, 6B, andonly the side chains of the motif leucines and Ile-689
6C). As a result, the positioning of helix 12 over theextensively contact the LBD in both noncrystallographic
ligand-binding pocket, as it is in the agonist-bound con-symmetry-related peptides. Mutation of Ile-689 to ala-
formation, would bury the positively charged dimethyl-nine reduces the ability of the NR box II peptide to inhibit
amino group of the OHT side chain within a hydrophobicthe binding of GRIP1 to ERa by z30-fold in a competition
cavity and produce steric clashes between the dimethyl-assay (data not shown). Remarkably, the residue pre-
aminoethyl region of side chain and the side chain ofceding the LXXLL motif differs for the three NR boxes
Leu-540.of GRIP1/TIF2. The sequence variability at this position
In functional terms, OHT is not, however, simply ªanmay explain the apparently different affinities of the NR
agonist with a side chain.º OHT binding promotes aboxes of TIF2 for the ERa (Voegel et al., 1998).
conformation of the LBD that is distinct from that stabi-
lized by either DES or E2 binding. These different confor-Helix 12 and the Regulation of AF-2 Activity
mations impose different restrictions on the positioningERa AF-2 activity is blocked by antagonists such as
OHT and RAL. The most striking feature of the structures of helix 12.
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Helices 3, 8, and 11 in the DES and E2 complexes are These mechanisms do not appear to be specific to
between one to two turns longer than they are in the OHT. The side chain of RAL, like that of OHT, sterically
OHT complex (Figure 6A and Brzozowski et al., 1997). hinders the agonist-bound conformation of helix 12
Helix 11 ends at Cys-530 in the DES and E2 complexes (Brzozowski et al., 1997). In addition, helix 11 appears
and at Tyr-526 in the OHT complex. Helix 12 begins to end at Met-528 in the RAL complex. This may result
at Leu-536 in the OHT complex. This appears to be from the distortions in the binding pocket in the vicinity
necessary; in the antagonist complex, Leu-536 forms a of His-524 directed by RAL binding (Brzozowski et al.,
cooperative network of nonpolar contacts and hydrogen 1997).
bonds with Glu-380 and Tyr-537 that stabilizes the N There is a great need for the improvement of existing
terminus of helix 12 (Figure 1B). Therefore, if helix 12 therapies and the development of new ones for the pre-
were to bind the static region of the AF-2 surface in the vention and treatment of breast cancer. While the tissue-
presence of agonist, the loop connecting helices 11 and selective antagonism of SERMs such as OHT and RAL
12 would be required to span z17 AÊ over five residues. is the result of numerous factors (Grainger and Metcalfe,
Although theoretically possible, this conformation would 1996; Grese et al., 1997; Jordan, 1998), dissection of
be highly strained and hence unlikely. In contrast, the the mechanisms of action of these ligands requires a
longer loop connecting helices 11 and 12 in the OHT comprehensive understanding of how they act on the
complex allows helix 12 to extend to the static region LBD and regulate its interactions with other cellular fac-
of the coactivator-binding groove. tors. Our studies have revealed, unexpectedly, that li-
In the DES and E2 complexes, helix 12 and the loop gand-mediated structural perturbations in and around
connecting helices 11 and 12 pack against helices 3 the ligand-binding pocket, and not simply side chain
and 11, whereas they do not in the OHT complex (Figures effects, contribute to receptor antagonism. Adjusting
2A and 2B and Brzozowski et al., 1997). Are the longer the balance between these two effects provides a novel
helices in the DES and E2 complexes dependent upon strategy for the design of improved SERMs.
the interactions helix 12 forms in the agonist-bound con-
formation? A recently described structure of the E2-LBD Experimental Procedures
complex suggests that they are not (Tanenbaum et al.,
1998). In this structure, a crystal-packing artifact forces Protein Expression and Purification
helix 12 to contact a symmetry-related molecule. Helix Human ERa LBD (residues 297±554) was expressed in BL21(DE3)-
pLysS (harboring a plasmid provided by P. Sigler) as described12 is clearly not positioned over the ligand-binding
previously (Seielstad et al., 1995). Bacterial lysates were applied topocket in this structure. Nevertheless, helices 3, 8, and
an estradiol-Sepharose column (Greene et al., 1980), and bound11 are longer than they are in the OHT complex (Figure
hERa LBD was carboxymethylated with 5 mM iodoacetic acid (Hegy6A). Hence, the longer helices of the agonist complexes
et al., 1996). Protein was eluted with 3 3 1025 M ligand in 30±100
occur independently of the positioning of helix 12 over ml of 50 mM Tris, 1 mM EDTA, 1 mM DTT, and 250 mM NaSCN (pH
the ligand-binding pocket and are instead a direct result 8.5). The hERa LBD was further purified by ion exchange chromatog-
of agonist binding. raphy (Resource Q, Pharmacia). Protein samples were analyzed by
SDS-PAGE, native PAGE, and electrospray ionization mass spec-The secondary structure differences between the ago-
trometry.nist complexes and the OHT complex arise from distinct
arrangements of packing interactions induced by the
GST-Pulldown Assaysdifferent ligands. A cooperative network of van der
A fusion between GST and amino acids 282±595 of hERa was con-Waals contacts, organized around DES or E2, between structed by subcloning the EcoRI fragment from pSG5 ERa-LBD
various hydrophobic residues from helices 3, 7, 8, and (Lopez et al., submitted) into pGEX-3X (Pharmacia). Mutations were
11 and the b hairpin appears to stabilize the longer introduced into this construct using the QuikChange Kit (Stratagene)
helices in the agonist complexes (Figures 4A and 6D). or by subcloning the appropriate fragments of mutant derivatives
of pSG5-ER-HEGO (Tora et al., 1989; Feng et al., 1998). All constructsThe placement of the OHT B ring forces many of the
were verified by automated sequencing.ligand-binding pocket residues that surround it to adopt
The wild-type and mutant GST-LBDs were expressed in BL21(DE3)conformations that are dramatically different from those
cells. The total [3H]E2 binding activity in each extract was determinedthey adopt in either the DES or E2 structures (see Re- by saturation analysis using a controlled pore glass bead (CPG)
sults). As a result, many of the interresidue packing inter- assay (Greene et al., 1988). GST-LBD protein levels were also moni-
actions present in the DES and E2 structures are either tored by Western blotting with a monoclonal antibody to hERa
absent or altered in the OHT structure (Figure 6D). These (H222) to confirm that the mutant GST-LBDs bound E2 with affinities
comparable to the wild-type protein. Cleared extracts containingstructural distortions apparently force the main chain
the GST-LBDs were incubated in buffer alone (50 mM Tris [pH 7.4],from residues 339 to 341, 421 to 423, and 527 to 530
150 mM NaCl, 2 mM EDTA, 1 mM DTT, 0.5% NP-40, and a protease(which form parts of helices 3, 8, and 11, respectively,
inhibitor cocktail) or with 1 mM of either DES or OHT for 1 hr at 48C.
in the agonist structures) to adopt an extended confor- Extract aliquots containing 30 pmol of binding activity, based on
mation in the OHT structure (Figures 6A±6D). the CPG assay, were then incubated with 10 ml glutathione-Sepha-
Therefore, the binding of OHT has two distinct effects rose-4B beads (Pharmacia) for 1 hr at 48C. Beads were washed five
on the positioning of helix 12, each of which contributes times with 20 mM HEPES (pH 7.4), 400 mM NaCl, and 0.05% NP-
40. 35S-labeled GRIP1 was synthesized using the TNT Coupled Retic-to antagonism. Helix 12 is prevented from being posi-
ulocyte Lysate System (Promega) and pSG5-GRIP1 (a gift of M.tioned over the ligand-binding pocket by the OHT side
Stallcup) as the template. Immobilized GST-LBDs were incubatedchain. In addition, the alternative packing arrangement
for 2.5 hr with 2.5 ml aliquots of crude translation reaction mixture
of ligand-binding pocket residues around OHT stabilizes diluted in 300 ml of Tris-buffered saline (TBS). After five washes in
a conformation of the LBD that permits helix 12 to reach TBS containing 0.05% NP-40, proteins were eluted by boiling the
the static region of the AF-2 surface and mimic bound beads for 10 min in sample buffer. Bound 35S-GRIP1 was visualized
by fluorography following SDS-PAGE.coactivator.
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Crystallization and Data Collection 91.6% of all residues in the model are in the core regions of the
Ramachandran plot and none are in the disallowed regions.Crystals of the DES-hERa LBD-GRIP1 NR box II peptide complex
were obtained by hanging drop vapor diffusion at 198C±218C. Prior The high resolution data set of the DES-LBD NR box II peptide
complex (Table 1) became available when the Rfree of the OHT-LBDto crystallization, the DES-LBD complex was incubated with a 2- to
4-fold molar excess of the GRIP1 NR box II peptide for 7±16 hr. model was z31%. Both monomers in the asymmetric unit of the DES
complex crystal were relocated using AMoRe and the incompletelySamples (2 ml) of this solution (4.3 mg/ml protein) were mixed with
2 ml of the reservoir buffer consisting of 25%±27% (w/v) PEG 4000, refined OHT-LBD model (with helix 12 and the loop between helices
11 and 12 removed) as the search model. The missing parts of the90 mM Tris (pH 8.75±9.0), and 180 mM Na acetate and suspended
over wells of the reservoir buffer. These crystals lie in the space model were built, and the rest of the model was corrected using
MOLOC and 2-fold averaged maps generated in DM. Initially, refine-group P21 with cell parameters a 5 54.09 AÊ , b 5 82.22 AÊ , c 5 58.04
AÊ , and b 5 111.34. Two molecules of the DES-LBD complex and of ment was carried out with REFMAC, using tight NCS restraints. At
later stages, the model was refined without NCS restraints usingthe coactivator peptide form the asymmetric unit. A crystal was
transferred to a cryosolvent solution containing 25% (w/v) PEG 4000, the simulated annealing, positional, and B-factor refinement proto-
cols in X-PLOR and a maximum-likelihood target. All B-factors were10% (w/v) ethylene glycol, 100 mM Tris (pH 8.5), 200 mM Na acetate,
and 10 mM peptide and frozen in an N2 stream at 21708C in a rayon refined isotropically, and anisotropic scaling and a bulk solvent
correction were used. The Rfree set contains a random sample ofloop. Diffraction data were measured at 21708C using the 300 mm
MAR image plate at the Stanford Synchrotron Radiation Laboratory 6.5% of all data. In refinement, all data between 27 and 2.03 AÊ (with
no s cutoff) were used. The final model is composed of residues(SSRL) beamline 7-1 (l 5 1.08 AÊ ).
Crystals of the OHT-hERa LBD complex were obtained by hanging 305±549 of monomer A, residues 305±461 and 470±549 of monomer
B, residues 687±697 of peptide A, residues 686±696 of peptide B,drop vapor diffusion at 218C±238C. Samples (2 ml) of a solution
containing 3.9 mg/ml complex and 2 ml of the reservoir solution two ligand molecules, 147 waters, two carboxymethyl groups, and
a chloride ion. According to PROCHECK, 93.7% of all residues incontaining 9% (w/v) PEG 8000, 6% (w/v) ethylene glycol, 50 mM
HEPES (pH 6.7), and 200 mM NaCl were mixed and suspended over the model are in the core regions of the Ramachandran plot, and
none are in the disallowed regions.wells of the reservoir solution. These crystals lie in the space group
P6522 with cell parameters a 5 b 5 58.24 AÊ and c 5 277.47 AÊ . The
asymmetric unit consists of a single LBD monomer; the dimer axis Illustrations
lies along a crystallographic 2-fold. A crystal was briefly incubated Figures 3C and 3D were created using GRASP (Nicholls et al., 1991).
in a cryoprotectant solution consisting of 10% (w/v) PEG 8000, 25% Figures 1, 2, 3A, 3B, 5, 6A, and 6D were generated using BOBSCRIPT
(w/v) ethylene glycol, 50 mM HEPES (pH 7.0), and 200 mM NaCl (Esnouf, 1997) and rendered using Raster3D (Merritt and Anderson,
and then flash frozen in liquid N2 suspended in a rayon loop. Diffrac- 1994). Figure 4 was generated using LIGPLOT (Wallace et al., 1995),
tion data were measured at 21708C at SSRL beamline 9-1 (l 5 and Figures 6B and 6C were created using MidasPlus (Huang et al.,
0.98 AÊ ) using a 345 MAR image plate. 1991). Figure 1A depicts peptide B; all other illustrations of the
The images of both data sets were processed with DENZO (Otwi- coactivator peptide depict peptide A.
nowski and Minor, 1997), and both data sets were scaled with
SCALEPACK (Otwinowski and Minor, 1997) using the default 23s Acknowledgments
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Note Added in Proof
During the course of this work, we received a draft of a manuscript
(Darimont, B.D., et al. [1998]. Structure and specificity of nuclear
receptor-coactivator interactions. Genes Dev. 12, 3343±3356) de-
scribing structural studies of the complex between TRb and the
GRIP1 NR box II peptide and biochemical studies of GRIP1 binding
to TRb and GR. We have included references to this work in the
text as Darimont et al. (1998). The general features of the TRb/GRIP1
